Filing Flows › Comparisons › VIR vs RGEN
Vir Biotechnology vs Repligen: VIR and RGEN compared
Vir Biotechnology is the larger company: $239M of revenue in its latest quarter (Q2 2026) against $209M for Repligen (Q3 2026). Vir Biotechnology is growing faster (197× against +11% a year earlier). Vir Biotechnology is more profitable, with an operating margin of 30.7% against -14.1%.
Where the money goes: VIR and RGEN
Vir Biotechnology (VIR) · Q2 2026
Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%, net earnings $80.1M, operating cash flow $123M. The chart follows the revenue to costs, profit and cash.
Repligen (RGEN) · Q3 2026
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart follows the revenue to costs, profit and cash.
| Vir Biotechnology (VIR) | Repligen (RGEN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $239M | $209M |
| Revenue growth, Y/Y | 197× | +11% |
| Operating margin | 30.7% | -14.1% |
| Net earnings | $80.1M | −$38.4M |
| Net margin | 33.5% | -18.4% |
| Operating cash flow | $123M | $43.1M |
| Free cash flow | $123M | $38.2M |
| Market value | — | $9.9B |
| Analysts’ mean target | — | $203.45 |
Where the revenue comes from
Vir Biotechnology
- License and collaboration revenue: $239M (100%)
- Grant revenue: $11K (0%)
Repligen
- Product: $209M (100%)
- Royalty and other revenue: $44K (0%)
Questions
Which is bigger, Vir Biotechnology or Repligen?
Vir Biotechnology is the larger company: $239M of revenue in its latest quarter (Q2 2026) against $209M for Repligen (Q3 2026).
Is Vir Biotechnology or Repligen growing faster?
Vir Biotechnology is growing faster (197× against +11% a year earlier).
Which is more profitable, Vir Biotechnology or Repligen?
Vir Biotechnology is more profitable, with an operating margin of 30.7% against -14.1%.
More: Vir Biotechnology earnings · how Vir Biotechnology makes money · Repligen earnings · how Repligen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.